Miranda, M B
Lauseker, M
Kraus, M-P
Proetel, U
Hanfstein, B
Fabarius, A
Baerlocher, G M
Heim, D
Hossfeld, D K
Kolb, H-J
Krause, S W
Nerl, C
Brümmendorf, T H
Verbeek, W
Fauser, A A
Prümmer, O
Neben, K
Hess, U
Mahlberg, R
Plöger, C
Flasshove, M
Rendenbach, B
Hofmann, W-K
Müller, M C
Pfirrmann, M
Hochhaus, A
Hasford, J
Hehlmann, R
Saußele, S
Article History
Received: 22 October 2015
Revised: 14 December 2015
Accepted: 23 December 2015
First Online: 9 February 2016
Competing interests
: BH has received honoraria from Bristol-Myers Squibb (BMS) and research funding from Novartis; SWK honoraria and research funding by Novartis; MCM honoraria and research funding from Novartis, BMS, ARIAD and Pfizer; MP honoraria from BMS and consultancy from Novartis; AH honoraria from Novartis, BMS, ARIAD, consultancy from Novartis and research funding from Novartis, ARIAD and Pfizer; RH research funding from Novartis and BMS and SS honoraria from Novartis, BMS, Pfizer, ARIAD and research funding from Novartis and BMS. The other authors declare no conflict of interest.